These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34680436)

  • 1. Predicting Cancer Drug Response In Vivo by Learning an Optimal Feature Selection of Tumour Molecular Profiles.
    Nguyen LC; Naulaerts S; Bruna A; Ghislat G; Ballester PJ
    Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic assessment of multi-gene predictors of pan-cancer cell line sensitivity to drugs exploiting gene expression data.
    Nguyen L; Dang CC; Ballester PJ
    F1000Res; 2016; 5():. PubMed ID: 28299173
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs.
    Punzi S; Meliksetian M; Riva L; Marocchi F; Pruneri G; Criscitiello C; Orsi F; Spaggiari L; Casiraghi M; Della Vigna P; Luzi L; Curigliano G; Pelicci PG; Lanfrancone L
    Cells; 2019 Jun; 8(6):. PubMed ID: 31216647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel Response Can Be Predicted With Interpretable Multi-Variate Classifiers Exploiting DNA-Methylation and miRNA Data.
    Bomane A; Gonçalves A; Ballester PJ
    Front Genet; 2019; 10():1041. PubMed ID: 31708973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision and recall oncology: combining multiple gene mutations for improved identification of drug-sensitive tumours.
    Naulaerts S; Dang CC; Ballester PJ
    Oncotarget; 2017 Nov; 8(57):97025-97040. PubMed ID: 29228590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Machine learning and feature selection for drug response prediction in precision oncology applications.
    Ali M; Aittokallio T
    Biophys Rev; 2019 Feb; 11(1):31-39. PubMed ID: 30097794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concise Polygenic Models for Cancer-Specific Identification of Drug-Sensitive Tumors from Their Multi-Omics Profiles.
    Naulaerts S; Menden MP; Ballester PJ
    Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32604779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling rectal cancer to advance neoadjuvant precision therapy.
    Janakiraman H; Zhu Y; Becker SA; Wang C; Cross A; Curl E; Lewin D; Hoffman BJ; Warren GW; Hill EG; Timmers C; Findlay VJ; Camp ER
    Int J Cancer; 2020 Sep; 147(5):1405-1418. PubMed ID: 31989583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research.
    Kawaguchi T; Foster BA; Young J; Takabe K
    J Mammary Gland Biol Neoplasia; 2017 Jun; 22(2):131-139. PubMed ID: 28451789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDXGEM: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patients.
    Kim Y; Kim D; Cao B; Carvajal R; Kim M
    BMC Bioinformatics; 2020 Jul; 21(1):288. PubMed ID: 32631229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Boolean-based machine learning framework identifies predictive biomarkers of HSP90-targeted therapy response in prostate cancer.
    Shin SY; Centenera MM; Hodgson JT; Nguyen EV; Butler LM; Daly RJ; Nguyen LK
    Front Mol Biosci; 2023; 10():1094321. PubMed ID: 36743211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.
    Yu J; Qin B; Moyer AM; Sinnwell JP; Thompson KJ; Copland JA; Marlow LA; Miller JL; Yin P; Gao B; Minter-Dykhouse K; Tang X; McLaughlin SA; Moreno-Aspitia A; Schweitzer A; Lu Y; Hubbard J; Northfelt DW; Gray RJ; Hunt K; Conners AL; Suman VJ; Kalari KR; Ingle JN; Lou Z; Visscher DW; Weinshilboum R; Boughey JC; Goetz MP; Wang L
    Breast Cancer Res; 2017 Dec; 19(1):130. PubMed ID: 29212525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
    Rivera M; Fichtner I; Wulf-Goldenberg A; Sers C; Merk J; Patone G; Alp KM; Kanashova T; Mertins P; Hoffmann J; Stein U; Walther W
    Neoplasia; 2021 Jan; 23(1):21-35. PubMed ID: 33212364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer.
    Lindner AU; Carberry S; Monsefi N; Barat A; Salvucci M; O'Byrne R; Zanella ER; Cremona M; Hennessy BT; Bertotti A; Trusolino L; Prehn JHM
    Int J Cancer; 2020 Nov; 147(10):2891-2901. PubMed ID: 32700762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts.
    Mer AS; Ba-Alawi W; Smirnov P; Wang YX; Brew B; Ortmann J; Tsao MS; Cescon DW; Goldenberg A; Haibe-Kains B
    Cancer Res; 2019 Sep; 79(17):4539-4550. PubMed ID: 31142512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
    Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A
    Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
    Kang HN; Choi JW; Shim HS; Kim J; Kim DJ; Lee CY; Hong MH; Park SY; Park AY; Shin EJ; Lee SY; Pyo KH; Yun MR; Choi HM; Lee SS; Kim SY; Lee H; Paik S; Cho BC; Lee JG; Kim HR
    Lung Cancer; 2018 Oct; 124():168-178. PubMed ID: 30268457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
    Krepler C; Xiao M; Sproesser K; Brafford PA; Shannan B; Beqiri M; Liu Q; Xu W; Garman B; Nathanson KL; Xu X; Karakousis GC; Mills GB; Lu Y; Ahmed TA; Poulikakos PI; Caponigro G; Boehm M; Peters M; Schuchter LM; Weeraratna AT; Herlyn M
    Clin Cancer Res; 2016 Apr; 22(7):1592-602. PubMed ID: 26673799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-derived xenografts as compatible models for precision oncology.
    Cho SY
    Lab Anim Res; 2020; 36():14. PubMed ID: 32461927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.